Literature DB >> 10381797

Stimulation of epithelial sodium channel activity by the sulfonylurea glibenclamide.

A Chrabi1, J D Horisberger.   

Abstract

The amiloride-sensitive epithelial sodium channel (ENaC) contributes to the regulation of the sodium balance and blood pressure because it mediates a rate-limiting step in sodium transport across the epithelium of the distal nephron. The activity of ENaC is regulated by hormones, such as aldosterone and vasopressin, and by other intracellular or extracellular factors, but the mechanisms of these regulations are not yet well understood. It has been proposed that ENaC may be regulated by an associated ATP-binding cassette protein such as the cystic fibrosis conductance regulator or the K channel-associated sulfonylurea receptor. Glibenclamide, a known inhibitor of sulfonylurea receptor and cystic fibrosis conductance regulator, induced a dose-dependent and reversible stimulation (of the order of 40-50%) of the amiloride-sensitive current in oocytes expressing Xenopus ENaC, with a K1/2 of 45 +/- 5 microM. A similar effect was observed in oocytes expressing human ENaC, but not rat ENaC. Measurements performed with various combinations of rat and Xenopus subunits indicated that several subunits are involved in this effect. Glibenclamide also increased the transepithelial Na transport by the A6 Xenopus kidney cell line. Single-channel current recordings showed a doubling of the number of the open channels when glibenclamide was applied locally to the extracellular surface of the cell membrane. These results support the hypothesis of the existence of an associated ATP-binding cassette-type regulatory protein associated with the epithelial sodium channel.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381797

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Role of the C-terminal part of the extracellular domain of the alpha-ENaC in activation by sulfonylurea glibenclamide.

Authors:  Stephane Renauld; Ahmed Chraibi
Journal:  J Membr Biol       Date:  2009-08-21       Impact factor: 1.843

2.  8-(4-chlorophenylthio)-guanosine-3',5'-cyclic monophosphate-Na stimulates human alveolar fluid clearance by releasing external Na+ self-inhibition of epithelial Na+ channels.

Authors:  Dong-Yun Han; Hong-Guang Nie; Xue-Feng Su; Xue-Mei Shi; Deepa Bhattarai; Meimi Zhao; Run-Zhen Zhao; Katlin Landers; Hua Tang; Lin Zhang; Hong-Long Ji
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-11       Impact factor: 6.914

3.  Cpt-cAMP activates human epithelial sodium channels via relieving self-inhibition.

Authors:  Raul Molina; Dong-Yun Han; Xue-Feng Su; Run-Zhen Zhao; Meimi Zhao; Gretta M Sharp; Yongchang Chang; Hong-Long Ji
Journal:  Biochim Biophys Acta       Date:  2011-03-17

4.  Mechanism of action of novel lung edema therapeutic AP301 by activation of the epithelial sodium channel.

Authors:  Waheed Shabbir; Parastoo Scherbaum-Hazemi; Susan Tzotzos; Bernhard Fischer; Hendrik Fischer; Helmut Pietschmann; Rudolf Lucas; Rosa Lemmens-Gruber
Journal:  Mol Pharmacol       Date:  2013-09-27       Impact factor: 4.436

Review 5.  Mechano-sensitivity of ENaC: may the (shear) force be with you.

Authors:  Martin Fronius; Wolfgang G Clauss
Journal:  Pflugers Arch       Date:  2007-09-15       Impact factor: 3.657

6.  Serotonin decreases alveolar epithelial fluid transport via a direct inhibition of the epithelial sodium channel.

Authors:  Arnaud Goolaerts; Jérémie Roux; Michael T Ganter; Vadim Shlyonsky; Ahmed Chraibi; Renauld Stéphane; Frédérique Mies; Michael A Matthay; Robert Naeije; Sarah Sariban-Sohraby; Marybeth Howard; Jean-Francois Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2009-08-28       Impact factor: 6.914

7.  Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas' Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus.

Authors:  Charity Masilela; Brendon Pearce; Joven Jebio Ongole; Oladele Vincent Adeniyi; Mongi Benjeddou
Journal:  J Pers Med       Date:  2021-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.